Clinical laboratories certified under Clinical Laboratory Improvement Amendments can immediately begin using this kit to detect SARS-CoV-2, the virus that causes COVID-19.
PerkinElmer's RT-PCR test is marketed as an in vitro diagnostic device by meeting the requirements of the European In Vitro Diagnostic Directive and is available in over 30 countries worldwide.
PerkinElmer offers solutions to serve the diagnostics, life sciences, food and applied markets.
The company reported revenue of approximately USD 2.9bn in 2019, serves customers in 190 countries, and is a component of the S and P 500 index.
AgNovos Healthcare Receives Breakthrough Designation for Spine Device
Oasmia forms global partnership with Elevar for commercialisation of Apealea
Jazz Pharmaceuticals files JZP-258 NDA with FDA for treatment of cataplexy and EDS
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
Tanner Pharma Group Expands Leukine Emergency Access Programme
Nuclein to Expedite Commercialisation of Hand-Held PCR Test to Aid in COVID-19 Pandemic
Hackensack Meridian Health licenses rapid test for COVID-19 to T2 Biosystems